Personalized vaccine combined with immunotherapy and chemo after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery for pancreatic cancer with clear margins (R0 resection) and have not received other treatments before surgery.
- You are in generally good health (able to do daily activities with little or no help).
- Your blood counts and organ function tests are within acceptable limits.
- You do not have other active cancers, uncontrolled infections, or serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.